TPST
Tempest Therapeutics Inc (TPST)
Healthcare • NASDAQ • $0.61-1.54%
- Symbol
- TPST
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.61
- Daily Change
- -1.54%
- Market Cap
- $10.54M
- Trailing P/E
- N/A
- Forward P/E
- -0.52
- 52W High
- $11.13
- 52W Low
- $0.62
- Analyst Target
- $7.00
- Dividend Yield
- 0.00%
- Beta
- -1.71
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to d…
Company websiteResearch TPST on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.